Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents

Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee

Research output: Contribution to journalArticle

Abstract

Milrinone is a type 3 phosphodiesterase inhibitor used to improve cardiac output in critically ill infants and children. Milrinone is primarily excreted unchanged in the urine, raising concerns for toxic accumulation in the setting of renal dysfunction of critical illness. We developed a population pharmacokinetic model of milrinone using nonlinear mixed-effects modeling in NONMEM to perform dose-exposure simulations in children with variable renal function. We included children aged <21 years who received intravenous milrinone per clinical care. Plasma milrinone concentrations were measured using a validated liquid chromatography–tandem mass spectrometry assay (range 1-5000 ng/mL). We performed dose-exposure simulations targeting steady-state therapeutic concentrations of 100-300 ng/mL previously established in adults and children with cardiac dysfunction. We simulated concentrations over 48 hours in typical subjects with decreasing creatinine clearance (CrCl), estimated using the updated bedside Schwartz equation. Seventy-four patients contributed 111 plasma samples (concentration range, 4-634 ng/mL). The median (range) postmenstrual age (PMA) was 3.7 years (0-18), and median weight (WT) was 13.1 kg (2.6-157.7). The median serum creatinine and CrCl were 0.5 mg/dL (0.1-3.1) and 117.2 mL/min/1.73 m2 (13.1-261.3), respectively. A 1-compartment model characterized the pharmacokinetic data well. The final model parameterization was: Clearance (L/h) = 15.9*(WT [kg] / 70)0.75* (PMA1.12 / (67.71.12+PMA1.12)*(CrCl / 117)0.522; and Volume of Distribution (L) = 32.2*(WT [kg] / 70). A loading dose of 50 µg/kg followed by a continuous infusion of 0.5 µg/kg/min resulted in therapeutic concentrations, except when CrCl was severely impaired at ≤30 mL/min/1.73 m2. In this setting, a 25 µg/kg loading dose and 0.25 µg/kg/min continuous infusion resulted in therapeutic exposures.

Original languageEnglish (US)
JournalJournal of Clinical Pharmacology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Milrinone
Creatinine
Pharmacokinetics
Population
Weights and Measures
Critical Illness
Phosphodiesterase 3 Inhibitors
Kidney
Poisons
Cardiac Output
Mass Spectrometry
Therapeutics
Urine
Serum

Keywords

  • children
  • creatinine clearance
  • infants
  • milrinone
  • pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee (2019). Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents. Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.1499

Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents. / Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee.

In: Journal of Clinical Pharmacology, 01.01.2019.

Research output: Contribution to journalArticle

Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee 2019, 'Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents', Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.1499
Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee. Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents. Journal of Clinical Pharmacology. 2019 Jan 1. https://doi.org/10.1002/jcph.1499
Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee. / Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents. In: Journal of Clinical Pharmacology. 2019.
@article{ec30cacab8504b7bb2f79417a59de21d,
title = "Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents",
abstract = "Milrinone is a type 3 phosphodiesterase inhibitor used to improve cardiac output in critically ill infants and children. Milrinone is primarily excreted unchanged in the urine, raising concerns for toxic accumulation in the setting of renal dysfunction of critical illness. We developed a population pharmacokinetic model of milrinone using nonlinear mixed-effects modeling in NONMEM to perform dose-exposure simulations in children with variable renal function. We included children aged <21 years who received intravenous milrinone per clinical care. Plasma milrinone concentrations were measured using a validated liquid chromatography–tandem mass spectrometry assay (range 1-5000 ng/mL). We performed dose-exposure simulations targeting steady-state therapeutic concentrations of 100-300 ng/mL previously established in adults and children with cardiac dysfunction. We simulated concentrations over 48 hours in typical subjects with decreasing creatinine clearance (CrCl), estimated using the updated bedside Schwartz equation. Seventy-four patients contributed 111 plasma samples (concentration range, 4-634 ng/mL). The median (range) postmenstrual age (PMA) was 3.7 years (0-18), and median weight (WT) was 13.1 kg (2.6-157.7). The median serum creatinine and CrCl were 0.5 mg/dL (0.1-3.1) and 117.2 mL/min/1.73 m2 (13.1-261.3), respectively. A 1-compartment model characterized the pharmacokinetic data well. The final model parameterization was: Clearance (L/h) = 15.9*(WT [kg] / 70)0.75* (PMA1.12 / (67.71.12+PMA1.12)*(CrCl / 117)0.522; and Volume of Distribution (L) = 32.2*(WT [kg] / 70). A loading dose of 50 µg/kg followed by a continuous infusion of 0.5 µg/kg/min resulted in therapeutic concentrations, except when CrCl was severely impaired at ≤30 mL/min/1.73 m2. In this setting, a 25 µg/kg loading dose and 0.25 µg/kg/min continuous infusion resulted in therapeutic exposures.",
keywords = "children, creatinine clearance, infants, milrinone, pharmacokinetics",
author = "{Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee} and Hornik, {Christoph P.} and Ram Yogev and Mourani, {Peter M.} and Watt, {Kevin M.} and Sullivan, {Janice E.} and Atz, {Andrew M.} and David Speicher and Amira Al-Uzri and Michelle Adu-Darko and Payne, {Elizabeth H.} and Gelber, {Casey E.} and Susan Lin and Barrie Harper and Chiara Melloni and Michael Cohen-Wolkowiez and Daniel Gonzalez",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/jcph.1499",
language = "English (US)",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents

AU - Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee

AU - Hornik, Christoph P.

AU - Yogev, Ram

AU - Mourani, Peter M.

AU - Watt, Kevin M.

AU - Sullivan, Janice E.

AU - Atz, Andrew M.

AU - Speicher, David

AU - Al-Uzri, Amira

AU - Adu-Darko, Michelle

AU - Payne, Elizabeth H.

AU - Gelber, Casey E.

AU - Lin, Susan

AU - Harper, Barrie

AU - Melloni, Chiara

AU - Cohen-Wolkowiez, Michael

AU - Gonzalez, Daniel

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Milrinone is a type 3 phosphodiesterase inhibitor used to improve cardiac output in critically ill infants and children. Milrinone is primarily excreted unchanged in the urine, raising concerns for toxic accumulation in the setting of renal dysfunction of critical illness. We developed a population pharmacokinetic model of milrinone using nonlinear mixed-effects modeling in NONMEM to perform dose-exposure simulations in children with variable renal function. We included children aged <21 years who received intravenous milrinone per clinical care. Plasma milrinone concentrations were measured using a validated liquid chromatography–tandem mass spectrometry assay (range 1-5000 ng/mL). We performed dose-exposure simulations targeting steady-state therapeutic concentrations of 100-300 ng/mL previously established in adults and children with cardiac dysfunction. We simulated concentrations over 48 hours in typical subjects with decreasing creatinine clearance (CrCl), estimated using the updated bedside Schwartz equation. Seventy-four patients contributed 111 plasma samples (concentration range, 4-634 ng/mL). The median (range) postmenstrual age (PMA) was 3.7 years (0-18), and median weight (WT) was 13.1 kg (2.6-157.7). The median serum creatinine and CrCl were 0.5 mg/dL (0.1-3.1) and 117.2 mL/min/1.73 m2 (13.1-261.3), respectively. A 1-compartment model characterized the pharmacokinetic data well. The final model parameterization was: Clearance (L/h) = 15.9*(WT [kg] / 70)0.75* (PMA1.12 / (67.71.12+PMA1.12)*(CrCl / 117)0.522; and Volume of Distribution (L) = 32.2*(WT [kg] / 70). A loading dose of 50 µg/kg followed by a continuous infusion of 0.5 µg/kg/min resulted in therapeutic concentrations, except when CrCl was severely impaired at ≤30 mL/min/1.73 m2. In this setting, a 25 µg/kg loading dose and 0.25 µg/kg/min continuous infusion resulted in therapeutic exposures.

AB - Milrinone is a type 3 phosphodiesterase inhibitor used to improve cardiac output in critically ill infants and children. Milrinone is primarily excreted unchanged in the urine, raising concerns for toxic accumulation in the setting of renal dysfunction of critical illness. We developed a population pharmacokinetic model of milrinone using nonlinear mixed-effects modeling in NONMEM to perform dose-exposure simulations in children with variable renal function. We included children aged <21 years who received intravenous milrinone per clinical care. Plasma milrinone concentrations were measured using a validated liquid chromatography–tandem mass spectrometry assay (range 1-5000 ng/mL). We performed dose-exposure simulations targeting steady-state therapeutic concentrations of 100-300 ng/mL previously established in adults and children with cardiac dysfunction. We simulated concentrations over 48 hours in typical subjects with decreasing creatinine clearance (CrCl), estimated using the updated bedside Schwartz equation. Seventy-four patients contributed 111 plasma samples (concentration range, 4-634 ng/mL). The median (range) postmenstrual age (PMA) was 3.7 years (0-18), and median weight (WT) was 13.1 kg (2.6-157.7). The median serum creatinine and CrCl were 0.5 mg/dL (0.1-3.1) and 117.2 mL/min/1.73 m2 (13.1-261.3), respectively. A 1-compartment model characterized the pharmacokinetic data well. The final model parameterization was: Clearance (L/h) = 15.9*(WT [kg] / 70)0.75* (PMA1.12 / (67.71.12+PMA1.12)*(CrCl / 117)0.522; and Volume of Distribution (L) = 32.2*(WT [kg] / 70). A loading dose of 50 µg/kg followed by a continuous infusion of 0.5 µg/kg/min resulted in therapeutic concentrations, except when CrCl was severely impaired at ≤30 mL/min/1.73 m2. In this setting, a 25 µg/kg loading dose and 0.25 µg/kg/min continuous infusion resulted in therapeutic exposures.

KW - children

KW - creatinine clearance

KW - infants

KW - milrinone

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=85069830116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069830116&partnerID=8YFLogxK

U2 - 10.1002/jcph.1499

DO - 10.1002/jcph.1499

M3 - Article

AN - SCOPUS:85069830116

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

ER -